Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.

Combinations of dacarbazine (DTIC) and other cytotoxic agents or alpha-interferon were given to 136 patients in five different regimens. The total response rate was 32% (95% confidence interval 24-40%); 13% had a complete remission. Female patients had a significantly higher chance of response than...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulder, N. H., van der Graaf, W. T., Willemse, P. H., Koops, H. S., de Vries, E. G., Sleijfer, D. T.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033382/
https://www.ncbi.nlm.nih.gov/pubmed/7522510
_version_ 1782136825572229120
author Mulder, N. H.
van der Graaf, W. T.
Willemse, P. H.
Koops, H. S.
de Vries, E. G.
Sleijfer, D. T.
author_facet Mulder, N. H.
van der Graaf, W. T.
Willemse, P. H.
Koops, H. S.
de Vries, E. G.
Sleijfer, D. T.
author_sort Mulder, N. H.
collection PubMed
description Combinations of dacarbazine (DTIC) and other cytotoxic agents or alpha-interferon were given to 136 patients in five different regimens. The total response rate was 32% (95% confidence interval 24-40%); 13% had a complete remission. Female patients had a significantly higher chance of response than male patients: 46% vs 23%. There was also a difference in complete response rate: 25% vs 9%. The overall survival was 6 months; 8% of patients had a response of more than 6 months and 2% of more than 2 years. Although response rates vary among the various regimens described in the literature, the complete response rates are quite similar and the long-term disease-free survival of these combinations may be similar to that of dacarbazine alone.
format Text
id pubmed-2033382
institution National Center for Biotechnology Information
language English
publishDate 1994
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20333822009-09-10 Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma. Mulder, N. H. van der Graaf, W. T. Willemse, P. H. Koops, H. S. de Vries, E. G. Sleijfer, D. T. Br J Cancer Research Article Combinations of dacarbazine (DTIC) and other cytotoxic agents or alpha-interferon were given to 136 patients in five different regimens. The total response rate was 32% (95% confidence interval 24-40%); 13% had a complete remission. Female patients had a significantly higher chance of response than male patients: 46% vs 23%. There was also a difference in complete response rate: 25% vs 9%. The overall survival was 6 months; 8% of patients had a response of more than 6 months and 2% of more than 2 years. Although response rates vary among the various regimens described in the literature, the complete response rates are quite similar and the long-term disease-free survival of these combinations may be similar to that of dacarbazine alone. Nature Publishing Group 1994-10 /pmc/articles/PMC2033382/ /pubmed/7522510 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Mulder, N. H.
van der Graaf, W. T.
Willemse, P. H.
Koops, H. S.
de Vries, E. G.
Sleijfer, D. T.
Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
title Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
title_full Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
title_fullStr Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
title_full_unstemmed Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
title_short Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
title_sort dacarbazine (dtic)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033382/
https://www.ncbi.nlm.nih.gov/pubmed/7522510
work_keys_str_mv AT muldernh dacarbazinedticbasedchemotherapyorchemoimmunotherapyofpatientswithdisseminatedmalignantmelanoma
AT vandergraafwt dacarbazinedticbasedchemotherapyorchemoimmunotherapyofpatientswithdisseminatedmalignantmelanoma
AT willemseph dacarbazinedticbasedchemotherapyorchemoimmunotherapyofpatientswithdisseminatedmalignantmelanoma
AT koopshs dacarbazinedticbasedchemotherapyorchemoimmunotherapyofpatientswithdisseminatedmalignantmelanoma
AT devrieseg dacarbazinedticbasedchemotherapyorchemoimmunotherapyofpatientswithdisseminatedmalignantmelanoma
AT sleijferdt dacarbazinedticbasedchemotherapyorchemoimmunotherapyofpatientswithdisseminatedmalignantmelanoma

Ejemplares similares